Active duty (AD) women suffer with chronic pelvic pain (CPP) while providers tackle diagnoses and treatments to keep them functional without contributing to the opioid epidemic. The purpose of this randomized trial was to determine the effectiveness of noninvasive, self-explanatory mindfulness-based stress reduction (MBSR) or self-paced healthy lifestyle (HL) interventions on CPP in AD women.
Methods:
A 6-week, interventional prospective study with AD women aged 21–55 years at Mountain Home (MTHM), Idaho, was conducted. Women were randomly assigned to MBSR (N = 21) or HL (N = 20) interventions. The primary outcome was pain perception. The secondary outcomes were depression and circulating cytokine levels.
Results:
Women in the MBSR group exhibited reduced pain interference (p < 0.01) and depression (p < 0.05) alongside decreased interleukin (IL)-4 (p < 0.05), IL-6 (p < 0.05), eotaxin (p < 0.05), monocyte chemoattractant protein-1 (p = 0.06), and interleukin-1 receptor antagonist (IL-1ra) (p < 0.01) and increased vascular endothelial growth factor (p < 0.05). Women in the HL group did not have changes in pain; however, they did exhibit reduced depression (p < 0.05) alongside decreased granulocyte–macrophage colony-stimulating factor (p < 0.05) and increased tumor necrosis factor alpha (p < 0.05), stromal cell-derived factor-1 (p < 0.01), and IL-1ra (p < 0.01).
Conclusions:
AD women receiving MBSR or HL had reduced depression scores and altered circulating cytokine levels; however, only those receiving MBSR had reduced pain perception. Findings support MBSR as an effective and viable behavioral treatment for AD women suffering from CPP and provide premise for larger randomized controlled studies.
Clinical Trial Registration:
MOCHI—An RCT of mindfulness as a treatment for CPP in AD Women NCT04104542 (September 26, 2019).
Get full access to this article
View all access options for this article.
References
1.
ACOG Committee on Practice Bulletins—Gynecology. ACOG practice bulletin no. 51. Chronic pelvic pain. Obstet Gynec, 2004; 103(3):589–605.
2.
YosefA, AhmedAG, Al-HussainiT, et al.Chronic pelvic pain: Pathogenesis and validated assessment. Mid East Fert Soc J, 2016; 21(4):205–222; doi: 10.1016/j.mefs.2016.08.001
3.
AyorindeAA, BhattacharyaS, DruceKL, et al.Chronic pelvic pain in women of reproductive and post-reproductive age: a population-based study. Euro J Pain, 2017; 21(3):445–455; doi: 10.1002/ejp.938
4.
Al-AbbadeyM, LiossiC, CurranN, et al.Treatment of female sexual pain disorders: A systematic review. J Sex Marital Therapy, 2016; 42(2):99–142; doi: 10.1080/0092623X.2015
5.
LattheP, MigniniL, GrayR, et al.Factors predisposing women to chronic pelvic pain: Systematic review. Br Med J, 2006; 332(7544):749–751; doi: 10.1136/bmj.38748.697465.55
6.
Statistics for Military 2020. Available from: https://www.statisticbrain.com/women-in-the-military-statistics/ [Last accessed: January 6, 2020].
7.
HarrisP. Women in combat: US military officially lifts ban on female soldiers. TheGuardian. 2013. Available from: https://www.theguardian.com/world/2013/jan/24/us-military-lifts-ban-women-combat [Last accessed: January 6, 2022].
8.
WrightJ Jr, AlbrightTS, GehrichAP, et al.Pelvic pain presenting in a combat environment. Mil Med, 2006; 171(9):841–843; doi: 10.7205/MILMED.171.9.841
9.
RyanGL, MengelingMA, SummersKM, et al.Hysterectomy risk in premenopausal-aged military veterans: associations with sexual assault and gynecologic symptoms. Am J Obstet Gynecol, 2016; 214(3):352.e351–e352.e313; doi: 10.1016/j.ajog.2015.10.003
10.
CichowskiSB, RogersRG, ClarkEA, et al.Military sexual trauma in female veterans is associated with chronic pain conditions. Mil Med, 2017; 182(9–10):e1895–e1899; doi: 10.7205/MILMED-D-16-00393
11.
CichowskiSB, RogersRG, KomesuY, et al.A 10-yr analysis of chronic pelvic pain and chronic opioid therapy in the women veteran population. Mil Med, 2018; 183(11–12):e635–e640; doi: 10.1093/milmed/usy114
12.
VallerandAH, CoslerP, HenningfieldJE, et al.Pain management strategies and lessons from the military: A narrative review. Pain Res Manage, 2015; 20(5):261–268; doi: 10.1155/2015/1
13.
Substance Abuse and Mental Health Services Administration. Opioid treatment program directory. Department of Health and Human Services. 2019. Available from: https://dpt2.samhsa.gov/treatment/directory.aspx [Last accessed: July 10, 2021].
14.
MathiasS, KuppermannM, LibermanR, et al.Chronic pelvic pain: Prevalence, health-related quality of life, and economic correlates. Obstet Gynecol, 1996; 87(3):321–327; doi: 10.1016/0029-7844(95)00458-0
15.
HigginsDM, KernsRD, BrandtCA, et al.Persistent pain and comorbidity among Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn Veterans. Pain Med, 2014; 15(5):782–790; doi: 10.1111/pme.12388
16.
Committee on Health Care for Underserved Women. Committee opinion no. 547: Health care for women in the military and women veterans. Obstet Gynecol, 2012; 120(6):1538–1542; doi: 10.1097/01.AOG.0000423821.70036.5a
17.
LevanderXA, OverlandMK. Care of women veterans. Med Clin N Am, 2015; 99(3):651; doi: 10.1016/j.mcna.2015.01.013
FosterDC, PiekarzKH, MurantTI, et al.Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis. Am J Obstet Gynecol, 2007; 196(4):346.e1–346.e8; doi: 10.1016/j.ajog.2006.12.038
20.
GerberS, BongiovanniAM, LedgerWJ, et al.Defective regulation of the proinflammatory immune response in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol, 2002; 186(4):696–700; doi: 10.1067/mob.2002.121869
GaoYJ, ZhangL, SamadOA, et al.JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci, 2009; 29(13):4096–4108; doi: 10.1523/JNEUROSCI.3623-08.2009
23.
HogeEA, BrandstetterK, MoshierS, et al.Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety, 2009; 26(5):447–455; doi: 10.1002/da.20564
24.
MaesM. Major depression and activation of the inflammatory response system. Adv Exp Med Biol, 1999; 461:25–46; doi: 10.1007/978-0-585-37970-8_2
25.
MillerRJ, JungH, BhangooSK, et al.Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol, 2009;(194):417–449; doi: 10.1007/978-3-540-79090-7_12
26.
RosenkranzMA, DavidsonRJ, MacCoonDG, et al.A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain Behav Immun, 2013; 27(1):174–184; doi: 10.1016/j.bbi.2012.10.013
27.
ZhangH, ZhangC. Vasoprotection by dietary supplements and exercise: Role of TNFα signaling. Exp Diabetes Res, 2012; 2012:972679; doi: 10.1155/2012/972679
28.
ChaoMT, AbercrombiePD, NakagawaS, et al.Prevalence and use of complementary health approaches among women with chronic pelvic pain in a prospective cohort study. Pain Med, 2015; 16(2):328–340; doi: 10.1111/pme.12585
29.
GarlandE, GaylordS, ParkJ. The role of Mindfulness in positive reappraisal. Explore, 2009; 5(1):37–44; doi: 10.1016/j.explore.2008.10.001
30.
BrottoLA, BergeronS, ZdaniukB, et al.A comparison of mindfulness-based cognitive therapy vs cognitive behavioral therapy for the treatment of provoked vestibulodynia in a hospital clinic setting. J Sex Med, 2019; 16(6):909–923; doi: 10.1016/j.jsxm.2019.04.002
31.
BaerRA, SmithGT, LykinsE, et al.Construct validity of the five facet mindfulness questionnaire in meditating and nonmeditating samples. Assessment, 2008; 15(3):329–342; doi: 10.1177/1073191107313003
32.
Jelsness-JørgensenL-P, MoumB, GrimstadT, et al.Validity, reliability, and responsiveness of the brief pain inventory in inflammatory bowel disease. Can J Gastroenterol Hepatol, 2016; 2016:5624261; doi: 10.1155/2016/5624261
33.
CrispCD, Hastings-TolsmaM, JonscherKR. Mindfulness-based stress reduction for military women with chronic pelvic pain: A feasibility study. Mil Med, 2016; 81(9):982–989; doi: 10.7205/milmed-d-15-00354
34.
FoxSD, FlynnE, AllenR. Mindfulness meditation for women with chronic pelvic pain, a pilot study. J Repro Med, 2011; 56(3–4):158–162.
35.
Witek-JanusekL, AlbuquerqueK, ChroniakKR, et al.Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun, 2008; 22(6):969–981; doi: 10.1016/j.bbi.2008.01.012
36.
BhanaA, RathodSD, SelohilweO, et al.The validity of the Patient Health Questionnaire for screening depression in chronic care patients in primary health care in South Africa. BMC Psych, 2015; 15:118; doi: 10.1186/s12888-015-0503-0
37.
KroenkeK, SpitzerRL, WilliamsJB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med, 2001; 16(9):606–613; doi: 10.1046/j.1525-1497.2001.016009606.x
38.
YangSF, WuTF, TsaiHT, et al.New markers in pelvic inflammatory disease. Clin Chim Acta, 2014; 431:118–124; doi: 10.1016/j.cca.2014.02.004
39.
ZhangJM, AnJ. Cytokines, inflammation, and pain. Int Anesthes Clin, 2007; 45(2):27–37; doi: 10.1097/AIA.0b013e318034194e
40.
GulE, Celik KavakE. Eotaxin levels in patients with primary dysmenorrhea. J Pain Res, 2018; 11:611–613; doi: 10.2147/JPR.S146603
41.
LiebregtsT, AdamB, BredackC, et al.Immune activation in patients with irritable bowel syndrome. Gastroenterology, 2007; 132(3):913–920; doi: 10.1053/j.gastro.2007.01.046
42.
StuartMJ, SinghalG, BauneBT. Systematic review of the neurobiological relevance of chemokines to psychiatric disorders. Front Cell Neurosci, 2015; 9:357; doi: 10.3389/fncel.2015.00357
43.
SugimotoMA, SousaLP, PinhoV, et al.Resolution of inflammation: What controls its onset?. Front Immunolog, 2016; 7:160; doi: 10.3389/fimmu.2016.00160
44.
LindenlaubT, SommerC. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol, 2003; 105(6):593–602; doi: 10.1007/s00401-003-0689-y
45.
OguraN, SatohK, AkutsuM, et al.MCP-1 production in temporomandibular joint inflammation. J Dent Res, 2010; 89(10):1117–1122; doi: 10.1177/0022034510376041
46.
TeixeiraAL, GamaCS, RochaNP, et al.Revisiting the role of eotaxin-1/CCL11 in psychiatric disorders. Front Psychiatry, 2018; 9:241; doi: 10.3389/fpsyt.2018.00241
47.
LeightonSP, NerurkarL, KrishnadasR, et al.Chemokines in depression in health and in inflammatory illness: A systematic review and meta-analysis. Mol Psychiatry, 2018; 23(1):48–58; doi: 10.1038/mp.2017.205
48.
Drosdzol-CopA, Skrzypulec-PlintaV, StojkoR. Serum and peritoneal fluid immunological markers in adolescent girls with chronic pelvic pain. Obstet Gynecol Surv, 2012; 67(6):374–381; doi: 10.1097/OGX.0b013e31825cb12b
49.
HulseRP. Role of VEGF-A in chronic pain. Oncotarget, 2017; 8(7):10775–10776; doi: 10.18632/oncotarget.14615
50.
DagherA, CuratoloA, SachdevM, et al.Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the multidisciplinary approach to the study of chronic pelvic pain (MAPP) research network. BJU Int, 2017; 120(1):130–142; doi: 10.1371/journal.pone.0206807
51.
PuchertM, AdamsV, LinkeA, et al.Evidence for the involvement of the CXCL12 system in the adaptation of skeletal muscles to physical exercise. Cell Signal, 2016; 28(9):1205–1215; doi: 10.1016/j.cellsig.2016.05.019
52.
Ortega-GómezA, PerrettiM, SoehnleinO. Resolution of inflammation: An integrated view. EMBO Mol Med, 2013; 5(5):661–674; doi: 10.1002/emmm.201202382
53.
LiY, LuMR, WeiYJ, et al.Dietary patterns and depression risk: A meta-analysis. Psych Res, 2017; 253:373–382; doi: 10.1016/j.psychres.2017.04.020
54.
GeneenLJ, MooreRA, ClarkeC, et al.Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. The Cochrane Database of System Reviews. 2017. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011279.pub3/pdf/CDSR/CD011279/CD011279_abstract.pdf [Last accessed: January 6, 2022].
55.
SongMR, LeeYS, BaekJD, et al.Physical activity status in adults with depression in the National Health and Nutrition Examination Survey, 2005–2006. Public Health Nurs, 2011; 29(3):208–217; doi: 10.1111/j.1525-1446.2011.00986.x
56.
Becerril-VillanuevaE, Perez-SanchezG, Alvarez-HerreraS, et al.Alterations in the levels of growth factors in adolescents with major depressive disorder: A longitudinal study during the treatment with fluoxetine. Mediators Inflamm, 2019; doi: 10.1155/2019/9130868
57.
LiuJJ, WeiYB, StrawbridgeR, et al.Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry, 2020; 25(2):339–350; doi: 10.1038/s41380-019-0474-5
58.
KooJW, DumanRS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs, 2009; 10(7): 664–671. PMID: 19579172, PMC3673287.
59.
Seckin-AlacE, AkhantSE, BastuE, et al.Elevated tissue levels of tumor necrosis factor-α in vulvar vestibulitis syndrome. Clin Exp Obstet Gynecol, 2014; 41(6):691–693. PMID: 25551965
60.
MaK, ZhangH, BalochZ. Pathogenetic and therapeutic applications of tumor necrosis factor-α (TNF-α) in major depressive disorder: A systematic review. Int J Mol Sci, 2016; 17(5):733; doi: 10.3390/ijms17050733
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
